Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.

IF 2.7 4区 医学 Q2 HEMATOLOGY
Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng
{"title":"Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.","authors":"Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng","doi":"10.1016/j.clml.2025.09.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.</p><p><strong>Methods: </strong>The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.</p><p><strong>Results: </strong>Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.</p><p><strong>Conclusions: </strong>Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.09.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.

Methods: The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.

Results: Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.

Conclusions: Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.

Waldenström巨球蛋白血症患者的死亡原因:一项基于人群的研究
背景:Waldenström巨球蛋白血症(WM)是一种罕见的惰性淋巴瘤,非巨球蛋白引起的死亡在治疗决策中变得越来越重要。本研究探讨了WM患者的死亡原因。方法:纳入1980 - 2016年监测、流行病学和最终结果(SEER)数据库中8894例确诊为WM的患者的数据。标准化死亡率(SMRs)用于评估与美国普通人群相比的相对死亡风险。结果:考虑到其他竞争事件,WM患者5年累积癌症、SMNs和非癌症原因的死亡发生率分别为8.6% (SD: 1.00e-05)、10.02% (SD: 1.17e-05)和16.14% (SD: 1.79e-05)。WM患者在诊断后第一年的癌症相关死亡指数SMR最高,为121.84 (95% CI, 103.8-142.11),此后下降。在非指标癌症相关死亡中,血液恶性肿瘤相关死亡显著增加,而实体肿瘤死亡仅在诊断后10年增加(SMR, 1.43; 95% CI, 1.06-1.9)。结论:目前,WM患者的非癌症相关死亡风险(主要是心血管疾病相关死亡)超过了癌症相关死亡风险。这些发现可能为WM患者未来的健康风险提供更好的指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信